Haematologica (Sep 2017)
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Sharmilan Thanendrarajan,
- Erming Tian,
- Pingping Qu,
- Pankaj Mathur,
- Carolina Schinke,
- Frits van Rhee,
- Maurizio Zangari,
- Leo Rasche,
- Niels Weinhold,
- Daisy Alapat,
- William Bellamy,
- Cody Ashby,
- Sandra Mattox,
- Joshua Epstein,
- Shmuel Yaccoby,
- Bart Barlogie,
- Antje Hoering,
- Michael Bauer,
- Brian A. Walker,
- Faith E. Davies,
- Gareth J. Morgan
Affiliations
- Sharmilan Thanendrarajan
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Erming Tian
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Pingping Qu
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Pankaj Mathur
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Carolina Schinke
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Frits van Rhee
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Maurizio Zangari
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Leo Rasche
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Niels Weinhold
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Daisy Alapat
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- William Bellamy
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Cody Ashby
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Sandra Mattox
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Joshua Epstein
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Shmuel Yaccoby
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Bart Barlogie
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Antje Hoering
- Cancer Research and Biostatistics, Seattle, WA, USA
- Michael Bauer
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Brian A. Walker
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Faith E. Davies
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- Gareth J. Morgan
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- DOI
- https://doi.org/10.3324/haematol.2017.168872
- Journal volume & issue
-
Vol. 102,
no. 9
Abstract
No abstracts available.